As of 2025-11-19, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is -84.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 2,247.51 mil USD. SRPT's TTM EBITDA according to its financial statements is -26.70 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 15.7x | 14.2x |
| Forward P/E multiples | 14.4x - 26.0x | 18.9x |
| Fair Price | (7.12) - 88.61 | 27.87 |
| Upside | -140.9% - 408.1% | 59.8% |
| Date | EV/EBITDA |
| 2025-11-18 | -84.17 |
| 2025-11-17 | -84.56 |
| 2025-11-14 | -89.54 |
| 2025-11-13 | -85.66 |
| 2025-11-12 | -86.36 |
| 2025-11-11 | -86.28 |
| 2025-11-10 | -83.50 |
| 2025-11-07 | -84.91 |
| 2025-11-06 | -84.95 |
| 2025-11-05 | -88.99 |
| 2025-11-04 | -79.31 |
| 2025-11-03 | -111.64 |
| 2025-10-31 | -109.92 |
| 2025-10-30 | -106.94 |
| 2025-10-29 | -107.72 |
| 2025-10-28 | -110.74 |
| 2025-10-27 | -107.92 |
| 2025-10-24 | -105.22 |
| 2025-10-23 | -101.61 |
| 2025-10-22 | -103.88 |
| 2025-10-21 | -107.33 |
| 2025-10-20 | -106.16 |
| 2025-10-17 | -104.04 |
| 2025-10-16 | -107.29 |
| 2025-10-15 | -102.83 |
| 2025-10-14 | -99.81 |
| 2025-10-13 | -101.88 |
| 2025-10-10 | -102.47 |
| 2025-10-09 | -106.47 |
| 2025-10-08 | -107.45 |
| 2025-10-07 | -106.43 |
| 2025-10-06 | -106.98 |
| 2025-10-03 | -104.55 |
| 2025-10-02 | -103.41 |
| 2025-10-01 | -91.54 |
| 2025-09-30 | -91.34 |
| 2025-09-29 | -89.58 |
| 2025-09-26 | -87.77 |
| 2025-09-25 | -85.26 |
| 2025-09-24 | -87.38 |
| 2025-09-23 | -86.09 |
| 2025-09-22 | -88.91 |
| 2025-09-19 | -84.13 |
| 2025-09-18 | -88.40 |
| 2025-09-17 | -82.64 |
| 2025-09-16 | -86.75 |
| 2025-09-15 | -84.28 |
| 2025-09-12 | -83.97 |
| 2025-09-11 | -86.01 |
| 2025-09-10 | -83.30 |